Inmar Intelligence buy adds RxTransparent to its healthcare platform

Press enter to search
Close search
Open Menu

Inmar Intelligence buy adds RxTransparent to its healthcare platform

By David Salazar - 02/11/2020

Inmar Intelligence is hitting the ground running following its recent rebrand. The Winston-Salem, N.C.-based company has acquired Forerunner Holdings, developers of RxTransparent, a software-as-a-service platform that offers drug supply chain analytics, inventory transparency and regulatory compliance. 

Inmar Intelligence said that the acquisition adds to its offerings two solutions that can help its pharmacy clients improve efficiency and compliance with the Drug Supply Chain Security Act and the recent USP <800> rule change. 

With regard to supply chain, RxTransparent offers a cloud-based subscription services that streamlines product tracing, optimizes transactional transparency and improves the ease with which pharmacies can report incidents of counterfeit, suspect or stolen product. The company’s USP <800> compliance offering includes a proprietary database that includes every hazardous drug on the National Institute for Occupational Safety and Health’s tables. Inmar Intelligence said the platform allows users to create an assessment of risk that identifies a hazardous frug in their facility and develop safe handling practices around the product. 

The two offerings are interoperable and used together, can provide continuous purchase monitoring and alert users if a new hazardous drug enters a formulary, then adds a drug to the assessment of risk. 

“Achieving compliance within the healthcare industry is only getting more urgent and failure to comply is not an option,” said David Mounts, CEO and chairman of Inmar Intelligence. “Adding RXTransparent’s pharmacy compliance solutions to our already powerful healthcare platform provides our clients with an unmatched level of support to achieve and maintain compliance while saving time and protecting their staff, patients and facility.”

Inmar Intelligence said that it currently works with 85% of the nation’s hospitals and drug manufacturers, as well as more than 50,000 pharmacies. 

“By combining forces with Inmar Intelligence, RXTransparent will not only be able to secure U.S. drug supply chain and healthcare workers from hazardous drugs, but we can now unlock the potential for broader synergies and innovations across the entire US healthcare pharmacy supply chain,” said Dwight deVera, senior director of product strategy at Inmar Intelligence.